Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

Table 2 Tumor response according chemotherapy associated with trastuzumab (166 evaluable patients)¹

	Docetaxel + Trastuzumab N = 99	95% C.I.	Vinorelbine + Trastuzumab N = 67	95% C.I.	P*
ORR (CR+PR)	76 (77%)	68%-84%	38 (57%)	45%-68%	0.01
CR	16 (16%)		10 (15%)
PR	60 (61%)		28 (42%)
SD	18 (18%)		17 (25%)
PD	5 (5%)		12 (18%)
CBR (CR+PR+SD ≥ 6 months)	88 (89%)	81%-94%	51 (76%)	65%-85%	0.07

Abbreviations: C.I., confidence interval: RR, response rate: CR, complete remission: PR, partial remission: SD, stable disease: PD, progressing disease: CBR, clinical benefit rate
¹For 12 patients (7 receiving docetaxel and 5 receiving vinorelbine) tumor response was not available at the time of the analysis
*Chi square test.

ISSN: 1471-2407